RANBAXY

CORPORATE OFFICE: PLOT NO. 90, SECTOR-32, GURGAON-122001 (HARYANA), INDJA PHONE: +91-124-4135000 FAX: +91-124-4106490 E-mail: secretarial@ranbaxy.com

Press Statement

Gurgaon, Haryana, May 31, 2013: Ranbaxy today issued an advisory in public interest for Patients, Doctors and all its stakeholders.

All Ranbaxy products currently in the Indian market and globally are safe and efficacious. Ranbaxy stands by the quality of every medicine that the company makes and distributes in India and every country around the world.

Ranbaxy operates cGMP (Current Good Manufacturing Practice) compliant manufacturing facilities in India and several other countries across the globe. The company's India facilities are routinely inspected by Drug Controller General of India (DCGI) and many other leading global regulatory agencies.

Ranbaxy remains committed to its philosophy of 'Quality and Patients First.'

Contacts:

Koji Ogawa Head - Corporate Services, Ranbaxy koji.ogawa@ranbaxy.com, +91-124-4135620

Krishnan Ramalingam General Manager, Corporate Communications, Ranbaxy krishnan.ramalingam@ranbaxy.com, 9810042540

Gaurav Chugh Senior Manager - Corporate Communications, Ranbaxy gaurav.chugh@ranbaxy.com, 9810471414

Sam